View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2014	May 05, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		55,841,785

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash	$ 84,193	$ 93,191
Accounts receivable, net of allowance for doubtful accounts of $284 and $299	13,287	12,957
Inventories	11,994	11,444
Prepaid expenses	2,016	1,712
Deferred income taxes	68	71
Other current assets	197	200
Total current assets	111,755	119,575
PROPERTY AND EQUIPMENT, net	17,826	17,933
INTANGIBLE ASSETS, net	20,659	22,226
GOODWILL	22,860	23,782
OTHER ASSETS	980	729
TOTAL ASSETS	174,080	184,245
CURRENT LIABILITIES:
Accounts payable	4,114	4,834
Deferred revenue	954	1,119
Accrued expenses	9,902	13,032
Total current liabilities	14,970	18,985
OTHER LIABILITIES	961	677
DEFERRED INCOME TAXES	3,435	3,437
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 55,842 and 55,632 shares issued and outstanding
Additional paid-in capital	339,651	338,674
Accumulated other comprehensive loss	(5,575)	(3,797)
Accumulated deficit	(179,362)	(173,731)
Total stockholders' equity	154,714	161,146
Total liabilities and stockholders' equity	$ 174,080	$ 184,245

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 284	$ 299
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000	120,000
Common stock, shares issued	55,842	55,632
Common stock, shares outstanding	55,842	55,632

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
NET REVENUES:
Product	$ 23,537	$ 20,962
Licensing and product development		202
Total revenue	23,537	21,164
COST OF PRODUCTS SOLD	9,610	9,135
Gross profit	13,927	12,029
OPERATING EXPENSES:
Research and development	2,481	3,357
Sales and marketing	11,340	13,874
General and administrative	5,724	5,387
Total operating expenses	19,545	22,618
Operating loss	(5,618)	(10,589)
OTHER INCOME (EXPENSE)	118	(47)
Loss before income taxes	(5,500)	(10,636)
INCOME TAX EXPENSE (BENEFIT)	131	(410)
NET LOSS	$ (5,631)	$ (10,226)
LOSS PER SHARE:
BASIC	$ (0.10)	$ (0.18)
DILUTED	$ (0.10)	$ (0.18)
SHARES USED IN COMPUTING LOSS PER SHARE:
BASIC	55,762	55,449
DILUTED	55,762	55,449

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,631)	$ (10,226)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	(1,778)	(1,125)
Other comprehensive loss	(1,778)	(1,125)
COMPREHENSIVE LOSS	$ (7,409)	$ (11,351)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
OPERATING ACTIVITIES:
Net loss	$ (5,631)	$ (10,226)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,406	1,394
Depreciation and amortization	1,539	1,602
Deferred income taxes	131	(410)
Changes in assets and liabilities
Accounts receivable	(402)	512
Inventories	(586)	(312)
Prepaid expenses and other assets	(280)	(1,545)
Accounts payable	(683)	2,263
Deferred revenue	(153)	37
Accrued expenses and other liabilities	(3,009)	(989)
Net cash used in operating activities	(7,668)	(7,674)
INVESTING ACTIVITIES:
Purchases of property and equipment	(647)	(480)
Net cash used in investing activities	(647)	(480)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	93	301
Repurchase of common stock	(521)	(743)
Net cash used in financing activities	(428)	(442)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(255)	(16)
NET DECREASE IN CASH	(8,998)	(8,612)
CASH, BEGINNING OF PERIOD	93,191	87,888
CASH, END OF PERIOD	84,193	79,276
Cash paid for:
Income taxes	$ 40	$ 27

The Company

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

The Company

1.	The Company

We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are sold to retail pharmacies and mass merchandisers as well as to consumers over the internet.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments.

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2014		December 31, 2013
Raw materials	$	6,815	$	6,700
Work in process		890		833
Finished goods		4,289		3,911

	$	11,994	$	11,444

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively.

Intangible Assets. Intangible assets consist of the following:


		March 31, 2014
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,338	$	(2,866	)	$	8,472
Patents and product rights	3-10		10,449		(7,601	)		2,848
Acquired technology	7		8,807		(3,132	)		5,675
Tradename	15		4,346		(759	)		3,587
Non-compete agreements	1-3		615		(538	)		77

		$	35,555	$	(14,896	)	$	20,659


		December 31, 2013
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,795	$	(2,701	)	$	9,094
Patents and product rights	3-10		10,449		(7,466	)		2,983
Acquired technology	7		9,162		(2,952	)		6,210
Tradename	15		4,521		(715	)		3,806
Non-compete agreements	1-3		787		(654	)		133

		$	36,714	$	(14,488	)	$	22,226

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.

We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist.

The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer.

Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively.

Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

Stockholders' Equity

3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Stockholders' Equity

3.	Stockholders’ Equity

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.

Total compensation cost related to stock options for the three months ended March 31, 2014 and 2013 was $719 and $662, respectively. Net cash proceeds from the exercise of stock options were $93 and $301 for the three months ended March 31, 2014 and 2013, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

The following table summarizes the stock option activity for the three months ended March 31, 2014:


	Options
Outstanding on January 1, 2014		5,271
Granted		1,168
Exercised		(22	)
Expired		(319	)
Forfeited		(70	)

Outstanding on March 31, 2014		6,028

Compensation cost of $687 and $732 related to restricted shares was recognized during the three months ended March 31, 2014 and 2013, respectively. In connection with the vesting of restricted shares, during the three months ended March 31, 2014 and 2013, 89 and 106 shares, respectively, with aggregate values of $521 and $743, respectively, were withheld and retired in satisfaction of minimum tax withholding obligations.

The following table summarizes restricted stock award activity for the three months ended March 31, 2014:


	Shares
Issued and unvested, January 1, 2014		653
Granted		403
Vested		(276	)
Forfeited		(16	)

Issued and unvested, March 31, 2014		764

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Accrued Expenses

3 Months Ended

Mar. 31, 2014

Payables And Accruals [Abstract]

Accrued Expenses

4.	Accrued Expenses


	March 31, 2014		December 31, 2013
Payroll and related benefits	$	2,763	$	5,827
Royalties		4,813		4,374
Professional fees		733		749
Other		1,593		2,082

	$	9,902	$	13,032

Income Taxes

3 Months Ended

Mar. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

5.	Income Taxes

During the three months ended March 31, 2014, we recorded foreign deferred tax expense of $131. During the three months ended March 31, 2013, we recorded a foreign deferred tax benefit of $410. The foreign deferred tax benefit is associated with certain Canadian research and development and investment tax credits and DNAG’s loss before income taxes in 2013. The 2013 income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.

In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of March 31, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three months ended March 31, 2014 and 2013.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2014

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

6.	Commitments and Contingencies

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

Business Segment Information

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Business Segment Information

7.	Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products primarily result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing, as well as, products sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

The following table summarizes segment information for the three months ended March 31, 2014 and 2013.


	Three Months Ended March 31,
	2014			2013
Net revenues:
OSUR	$	17,778		$	17,232
DNAG		5,759			3,932

Total	$	23,537		$	21,164

Operating income (loss):
OSUR	$	(6,394	)	$	(10,040	)
DNAG		776			(549	)

Total	$	(5,618	)	$	(10,589	)

Depreciation and amortization:
OSUR	$	776		$	777
DNAG		763			825

Total	$	1,539		$	1,602

Capital expenditures:
OSUR	$	439		$	243
DNAG		208			237

Total	$	647		$	480


	March 31, 2014			December 31, 2013
Total assets:
OSUR	$	122,675		$	130,848
DNAG		51,405			53,397

Total	$	174,080		$	184,245

Our products are sold principally in the United States and Europe.

The following table represents total revenues by geographic area, based on the location of the customer:


	Three Months Ended March 31,
	2014		2013
United States	$	17,406	$	16,040
Europe		4,001		2,846
Other regions		2,130		2,278

	$	23,537	$	21,164

The following table represents total long-lived assets by geographic area:


	March 31, 2014		December 31, 2013
United States	$	16,729	$	16,925
Canada		1,069		975
Other regions		28		33

	$	17,826	$	17,933

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Use of Estimates

Fair Value of Financial Instruments

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Inventories

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2014		December 31, 2013
Raw materials	$	6,815	$	6,700
Work in process		890		833
Finished goods		4,289		3,911

	$	11,994	$	11,444

Property and Equipment

Intangible Assets

Intangible Assets. Intangible assets consist of the following:


		March 31, 2014
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,338	$	(2,866	)	$	8,472
Patents and product rights	3-10		10,449		(7,601	)		2,848
Acquired technology	7		8,807		(3,132	)		5,675
Tradename	15		4,346		(759	)		3,587
Non-compete agreements	1-3		615		(538	)		77

		$	35,555	$	(14,896	)	$	20,659


		December 31, 2013
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,795	$	(2,701	)	$	9,094
Patents and product rights	3-10		10,449		(7,466	)		2,983
Acquired technology	7		9,162		(2,952	)		6,210
Tradename	15		4,521		(715	)		3,806
Non-compete agreements	1-3		787		(654	)		133

		$	36,714	$	(14,488	)	$	22,226

Goodwill

The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation.

Revenue Recognition

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.

Customer Sales Returns and Allowances

Deferred Revenue

Customer and Vendor Concentrations

Loss Per Share

Foreign Currency Translation

Accumulated Other Comprehensive Loss

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Inventories

Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2014		December 31, 2013
Raw materials	$	6,815	$	6,700
Work in process		890		833
Finished goods		4,289		3,911

	$	11,994	$	11,444

Intangible Assets

Intangible assets consist of the following:


		March 31, 2014
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,338	$	(2,866	)	$	8,472
Patents and product rights	3-10		10,449		(7,601	)		2,848
Acquired technology	7		8,807		(3,132	)		5,675
Tradename	15		4,346		(759	)		3,587
Non-compete agreements	1-3		615		(538	)		77

		$	35,555	$	(14,896	)	$	20,659


		December 31, 2013
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,795	$	(2,701	)	$	9,094
Patents and product rights	3-10		10,449		(7,466	)		2,983
Acquired technology	7		9,162		(2,952	)		6,210
Tradename	15		4,521		(715	)		3,806
Non-compete agreements	1-3		787		(654	)		133

		$	36,714	$	(14,488	)	$	22,226

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2014:


	Options
Outstanding on January 1, 2014		5,271
Granted		1,168
Exercised		(22	)
Expired		(319	)
Forfeited		(70	)

Outstanding on March 31, 2014		6,028

Summary of Restricted Stock Award Activity

The following table summarizes restricted stock award activity for the three months ended March 31, 2014:


	Shares
Issued and unvested, January 1, 2014		653
Granted		403
Vested		(276	)
Forfeited		(16	)

Issued and unvested, March 31, 2014		764

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2014

Payables And Accruals [Abstract]

Schedule of Accrued Expenses


	March 31, 2014		December 31, 2013
Payroll and related benefits	$	2,763	$	5,827
Royalties		4,813		4,374
Professional fees		733		749
Other		1,593		2,082

	$	9,902	$	13,032

Business Segment Information (Tables)

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Summary of Segment Information

The following table summarizes segment information for the three months ended March 31, 2014 and 2013.


	Three Months Ended March 31,
	2014			2013
Net revenues:
OSUR	$	17,778		$	17,232
DNAG		5,759			3,932

Total	$	23,537		$	21,164

Operating income (loss):
OSUR	$	(6,394	)	$	(10,040	)
DNAG		776			(549	)

Total	$	(5,618	)	$	(10,589	)

Depreciation and amortization:
OSUR	$	776		$	777
DNAG		763			825

Total	$	1,539		$	1,602

Capital expenditures:
OSUR	$	439		$	243
DNAG		208			237

Total	$	647		$	480


	March 31, 2014			December 31, 2013
Total assets:
OSUR	$	122,675		$	130,848
DNAG		51,405			53,397

Total	$	174,080		$	184,245

Presentation of Total Revenues and Long-Lived Assets by Geographic Area

The following table represents total revenues by geographic area, based on the location of the customer:


	Three Months Ended March 31,
	2014		2013
United States	$	17,406	$	16,040
Europe		4,001		2,846
Other regions		2,130		2,278

	$	23,537	$	21,164

The following table represents total long-lived assets by geographic area:


	March 31, 2014		December 31, 2013
United States	$	16,729	$	16,925
Canada		1,069		975
Other regions		28		33

	$	17,826	$	17,933

Summary of Significant Accounting Policies - Additional Information (Detail) shares in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Jul. 31, 2012 USD ($)	Mar. 31, 2014 USD ($) Customer shares	Mar. 31, 2013 USD ($) shares	Dec. 31, 2013 USD ($)
Product Information [Line Items]
Fair value of plan assets		$ 1,111,000		$ 677,000
Accumulated depreciation of property and equipment		$ 29,081,000		28,390,000
Percentage of excess of fair value on carrying value		13.00%
Amount of goodwill at period end		$ 22,860,000		23,782,000
Reserve for sales return and allowances		329,000		279,000
Deferred revenue		$ 954,000		1,119,000
Number of our customers, accounted for significant concentrations \| Customer		1
Concentration rate of accounts receivable		10.00%
Significant concentrations in revenues		$ 0	$ 0
Number of anti-dilutive securities excluded from EPS computation \| shares		6,792	5,997
Accumulated foreign currency adjustments included in other comprehensive loss amounted		$ 1,778,000	$ 1,125,000
Up Front Payment Arrangement [Member]
Product Information [Line Items]
Deferred revenue		$ 954,000		$ 1,119,000
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Product Information [Line Items]
Percentage of concentration risk		11.00%
Maximum [Member] \| Other Intangible Assets [Member]
Product Information [Line Items]
Useful life of building and other assets		10 years
Maximum [Member] \| Building [Member]
Product Information [Line Items]
Useful life of building and other assets		40 years
Minimum [Member] \| Other Intangible Assets [Member]
Product Information [Line Items]
Useful life of building and other assets		2 years
Minimum [Member] \| Building [Member]
Product Information [Line Items]
Useful life of building and other assets		20 years
DNA Genotek [Member]
Product Information [Line Items]
Fair value of goodwill		$ 25,179,000
Impairment of goodwill	$ 0
Number of third-party suppliers to manufacture DNAG's products		2

Summary of Significant Accounting Policies - Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2014	Dec. 31, 2013
Inventory Net [Abstract]
Raw materials	$ 6,815	$ 6,700
Work in process	890	833
Finished goods	4,289	3,911
Inventories	$ 11,994	$ 11,444

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross	$ 35,555	$ 36,714
Accumulated Amortization	(14,896)	(14,488)
Net	$ 20,659	$ 22,226
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	$ 11,338	$ 11,795
Accumulated Amortization	(2,866)	(2,701)
Net	8,472	9,094
Patent and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	10,449	10,449
Accumulated Amortization	(7,601)	(7,466)
Net	$ 2,848	$ 2,983
Patent and Product Rights [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	3 years	3 years
Patent and Product Rights [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Gross	$ 8,807	$ 9,162
Accumulated Amortization	(3,132)	(2,952)
Net	$ 5,675	$ 6,210
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years
Gross	$ 4,346	$ 4,521
Accumulated Amortization	(759)	(715)
Net	3,587	3,806
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	615	787
Accumulated Amortization	(538)	(654)
Net	$ 77	$ 133
Non-compete Agreements [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	1 year	1 year
Non-compete Agreements [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	3 years	3 years

Stockholders' Equity - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,406	$ 1,394
Net cash proceeds from the exercise of stock options	93	301
Income tax benefit realized from stock option exercises during period	0	0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 687	$ 732
Vesting of restricted shares, withheld and withholding obligations	89	106
Restricted shares of common stock, aggregate values	$ 521	$ 743
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	719	662
Net cash proceeds from the exercise of stock options	$ 93	$ 301

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2014 shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]
Options, Outstanding, Beginning balance	5,271
Options, Outstanding, Granted	1,168
Options, Outstanding, Exercised	(22)
Options, Outstanding, Expired	(319)
Options, Outstanding, Forfeited	(70)
Options, Outstanding, Ending balance	6,028

Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2014 shares
Equity [Abstract]
Shares, Issued and unvested, Beginning balance	653
Shares, Granted	403
Shares, Vested	(276)
Shares, Forfeited	(16)
Shares, Issued and unvested, Ending balance	764

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 2,763	$ 5,827
Royalties	4,813	4,374
Professional fees	733	749
Other	1,593	2,082
Accrued Expenses, Total	$ 9,902	$ 13,032

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]
Foreign deferred tax expense (benefits)	$ 131	$ (410)
U.S. federal income tax benefits	0	0
U.S. state income tax benefits	$ 0	$ 0

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Business Segment Information - Summary of Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenues	$ 23,537	$ 21,164
Operating income (loss)	(5,618)	(10,589)
Depreciation and amortization	1,539	1,602
Capital expenditures	647	480
Total assets	174,080		$ 184,245
OSUR [Member]
Segment Reporting Information [Line Items]
Net revenues	17,778	17,232
Operating income (loss)	(6,394)	(10,040)
Depreciation and amortization	776	777
Capital expenditures	439	243
Total assets	122,675		130,848
DNAG [Member]
Segment Reporting Information [Line Items]
Net revenues	5,759	3,932
Operating income (loss)	776	(549)
Depreciation and amortization	763	825
Capital expenditures	208	$ 237
Total assets	$ 51,405		$ 53,397

Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 23,537	$ 21,164
Long-lived assets	17,826		$ 17,933
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	17,406	16,040
Long-lived assets	16,729		16,925
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	4,001	2,846
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	2,130	$ 2,278
Long-lived assets	28		33
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 1,069		$ 975